Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2007
|
| gptkbp:ATCCode |
gptkb:L01XE08
|
| gptkbp:blackBoxWarning |
QT prolongation
|
| gptkbp:brand |
gptkb:Tasigna
|
| gptkbp:CASNumber |
gptkb:641571-10-0
|
| gptkbp:chemicalFormula |
gptkb:C28H22F3N7O
|
| gptkbp:contraindication |
hypokalemia
hypomagnesemia long QT syndrome |
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:drugClass |
protease inhibitor
antineoplastic agent |
| gptkbp:eliminationHalfLife |
17 hours
|
| gptkbp:form |
capsule
|
| gptkbp:genericName |
gptkb:nilotinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tasigna
|
| gptkbp:indication |
gptkb:chronic_myeloid_leukemia
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
gptkb:D_(Australia)
D (US) |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
rash QT prolongation myelosuppression |
| gptkbp:target |
gptkb:BCR-ABL
|
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|